28.88

2.23% 0.63

After Hours: 28.52 -0.36 -1.25%

Rapport Therapeutics Inc (RAPP)

Overview News Price History Discussions Forecast

Rapport Therapeutics Inc stock is traded at $28.88, with a volume of 305.57K. It is up +2.23% in the last 24 hours and down -4.37% over the past month. Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Previous Close:

$28.25

Open:

$28.86

24h Volume:

305.57K

Relative Volume:

0.85

Market Cap:

$1.38B

Revenue:

Net Income/Loss:

$-111.48M

P/E Ratio:

-10.08

EPS:

-2.865

Net Cash Flow:

$-88.09M

1W Performance:

+9.06%

1M Performance:

-4.37%

6M Performance:

+15.66%

1Y Performance:

+187.36%

1-Day Range:

$28.57

$30.72

1-Week Range:

$26.01

$30.72

52-Week Range:

$7.73

$42.27

Rapport Therapeutics Inc Stock (RAPP) Company Profile

Name

Rapport Therapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

857-321-8020

Address

99 HIGH STREET, BOSTON

Employee

Twitter

Next Earnings Date

2026-03-10

Latest SEC Filings

RAPP's Discussions on Twitter

Compare RAPP vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RAPP Rapport Therapeutics Inc	28.88	1.35B	0	-111.48M	-88.09M	-2.865
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-02-26	Initiated	Wells Fargo	Overweight
Nov-19-25	Initiated	BTIG Research	Buy
Sep-16-25	Initiated	Truist	Buy
Aug-06-25	Initiated	H.C. Wainwright	Buy
Apr-08-25	Initiated	Citizens JMP	Mkt Outperform
Jul-02-24	Initiated	Jefferies	Buy
Jul-02-24	Initiated	Stifel	Buy
Jul-02-24	Initiated	TD Cowen	Buy

View All

Rapport Therapeutics Inc Stock (RAPP) Latest News

Mar 24, 2026

Geopolitics Watch: Will Rapport Therapeutics Inc stock go up in YEAR2026 Price Targets & AI Driven Price Predictions - baoquankhu1.vn

Mar 24, 2026

(RAPP) Risk Channels and Responsive Allocation - Stock Traders Daily

Mar 24, 2026

Mar 21, 2026

RAPP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Mar 21, 2026

Mar 20, 2026

How Investors May Respond To Rapport Therapeutics (RAPP) Licensing RAP-219 To Tenacia In Greater China - Yahoo Finance

Mar 20, 2026

Mar 19, 2026

Analysts Offer Insights on Healthcare Companies: Immutep Ltd (OtherPRRUF), Coya Therapeutics, Inc. (COYA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail

Mar 19, 2026

Mar 18, 2026

Aug Selloffs: Why is Rapport Therapeutics Inc stock going up2026 Trends & Scalable Portfolio Growth Ideas - baoquankhu1.vn

Mar 18, 2026

Buyout Rumor: Does Rapport Therapeutics Inc have strong fundamentals2026 Highlights & Long-Term Capital Growth Strategies - baoquankhu1.vn

Mar 18, 2026

Sell Signal: Will Rapport Therapeutics Inc benefit from AI trends2026 Drop Watch & Fast Gain Swing Trade Alerts - baoquankhu1.vn

Mar 18, 2026

Mar 17, 2026

What hedge funds are buying Rapport Therapeutics Inc2026 Fundamental Recap & Reliable Entry Point Trade Alerts - baoquankhu1.vn

Mar 17, 2026

Update Recap: Why is Rapport Therapeutics Inc stock going up2026 Volume Leaders & Fast Exit and Entry Strategy Plans - baoquankhu1.vn

Mar 17, 2026

Mar 16, 2026

Whats the outlook for Rapport Therapeutics Incs sectorWeekly Risk Report & Safe Swing Trade Setups - baoquankhu1.vn

Mar 16, 2026

Take Profit: Is Rapport Therapeutics Inc undervalued by DCF analysisWeekly Loss Report & Stock Portfolio Risk Management - baoquankhu1.vn

Mar 16, 2026

Truist reiterates Rapport Therapeutics stock rating on phase 3 plans By Investing.com - Investing.com Canada

Mar 16, 2026

Truist reiterates Rapport Therapeutics stock rating on phase 3 plans - Investing.com

Mar 16, 2026

Mar 15, 2026

Baker BROS. Advisors LP Has $45.95 Million Position in Rapport Therapeutics, Inc. $RAPP - MarketBeat

Mar 15, 2026

Mar 14, 2026

HC Wainwright & Co. Initiates Coverage of Rapport Therapeutics (RAPP) with Buy Recommendation - MSN

Mar 14, 2026

Rapport Therapeutics (NASDAQ:RAPP) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat

Mar 14, 2026

Why Rapport Therapeutics (RAPP) Is Down 7.9% After RAP-219 China Deal And Shelf Filing - simplywall.st

Mar 14, 2026

Q1 EPS Forecast for Rapport Therapeutics Boosted by Analyst - Defense World

Mar 14, 2026

Mar 13, 2026

Q1 EPS Estimate for Rapport Therapeutics Lifted by Analyst - MarketBeat

Mar 13, 2026

Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (RAPP), SAB Biotherapeutics (SABS) and Encompass Health (EHC) - The Globe and Mail

Mar 13, 2026

(RAPP) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Mar 13, 2026

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives $50.80 Consensus PT from Brokerages - Defense World

Mar 13, 2026

Mar 12, 2026

Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 7.7%Should You Sell? - MarketBeat

Mar 12, 2026

Analysts Offer Insights on Healthcare Companies: Sana Biotechnology (SANA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail

Mar 12, 2026

Equities Analysts Offer Predictions for RAPP FY2030 Earnings - MarketBeat

Mar 12, 2026

Capital International Investors Buys 800,000 Shares of Rapport Therapeutics, Inc. $RAPP - MarketBeat

Mar 12, 2026

Mar 11, 2026

Day Trade: Will Rapport Therapeutics Inc stock go up in YEARMarket Weekly Review & Scalable Portfolio Growth Methods - baoquankhu1.vn

Mar 11, 2026

Rapport Therapeutics (NASDAQ:RAPP) Price Target Raised to $46.00 at Wells Fargo & Company - MarketBeat

Mar 11, 2026

BTIG raises Rapport Therapeutics stock price target on trial progress By Investing.com - Investing.com Canada

Mar 11, 2026

Jones Trading reiterates Rapport Therapeutics stock rating on epilepsy progress - Investing.com Canada

Mar 11, 2026

Stifel reiterates Rapport Therapeutics stock rating after results By Investing.com - Investing.com Canada

Mar 11, 2026